K-group, Beta, Inc., A Wholly Owned Subsidiary Of Zentalis Pharmaceuticals, Inc
Clinical trials sponsored by K-group, Beta, Inc., A Wholly Owned Subsidiary Of Zentalis Pharmaceuticals, Inc, explained in plain language.
-
New drug azenosertib takes on Chemo-Resistant ovarian cancer in phase 3 trial
Disease control Recruiting nowThis phase 3 study tests whether a new drug called azenosertib works better than standard chemotherapy for people with a specific type of ovarian cancer that no longer responds to platinum-based treatments. The trial enrolls 420 women whose tumors have a high level of a protein c…
Phase: PHASE3 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for drug-resistant ovarian cancer: experimental pill targets tumor weakness
Disease control Recruiting nowThis study tests an experimental drug called azenosertib (ZN-c3) in people with a specific type of ovarian, fallopian tube, or peritoneal cancer that no longer responds to platinum chemotherapy. The drug aims to shrink or control tumors by blocking a protein that cancer cells nee…
Phase: PHASE2 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New combo therapy targets Platinum-Resistant ovarian cancer
Disease control Recruiting nowThis early-phase study tests a new drug called azenosertib (ZN-c3) combined with standard chemotherapy or bevacizumab in people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based treatment. About 172 participants will receive differen…
Phase: PHASE1 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC